Fezakinumab,Abbexa,abx831186

Fezakinumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting IL22, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Fezakinumab has been used in trials studying the treatment of Atopic Dermatitis and Rheumatoid Arthritis.

Host

Human

Reactivity

Human

Application

ELISA, WB

Conjugate

Unconjugated

Platform ID

BAB612189671

Abbexa

Headquarters

181 Cambridge Science Park Cambridge, CB4 0GJ United Kingdom

Contact

Tel: +44 (0) 1223 755950
Fax: +44 (0) 1223 755951

Product Specifications

Specifications

NameFezakinumab
Cat. No.abx831186
HostHuman
IsotypeIgG1 Lambda
ReactivityHuman
ConjugationUnconjugated
ApplicationELISA, WB
Working DilutionsOptimal dilutions/concentrations should be determined by the end user.
ClonalityMonoclonal
ConcentrationBatch-dependent, typically between 0.5-2.0 mg/ml.
TargetIL22
PurityPurified from cell culture supernatants by Protein A/G chromatography.
Appearance/FormLiquid
Formulation0.01 M PBS. pH 7.4.
StorageAliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Regulatory StatusResearch Use Only

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.